{
    "clinical_study": {
        "@rank": "104009", 
        "acronym": "SWIFT PRIME", 
        "arm_group": [
            {
                "arm_group_label": "IV t-PA with SOLITAIRE\u2122 FR Device", 
                "arm_group_type": "Experimental", 
                "description": "Dual IV tPA therapy and adjunctive treatment with the Solitaire FR"
            }, 
            {
                "arm_group_label": "IV t-PA", 
                "arm_group_type": "Active Comparator", 
                "description": "IV infusion of tPA"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is to determine if patients experiencing an Acute Ischemic Stroke due to large\n      vessel occlusion, treated with combined IV t-PA and Solitaire FR within 6 hours of symptom\n      onset have less stroke-related disability than those patients treated with IV t-PA alone."
        }, 
        "brief_title": "Solitaire\u2122 FR as Primary Treatment for Acute Ischemic Stroke", 
        "completion_date": {
            "#text": "September 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Ischemic Stroke", 
        "condition_browse": {
            "mesh_term": [
                "Ischemia", 
                "Stroke", 
                "Cerebral Infarction"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age 18 - 85\n\n          2. Clinical signs consistent with acute ischemic stroke\n\n          3. No prestroke functional dependence (prestroke Modified Rankin Score \u2264 1)\n\n          4. NIHSS \u2265 8 and < 30 at the time of randomization\n\n          5. Initiation of IV t-PA within 4.5 hours of onset of stroke symptoms (onset time is\n             defined as the last time when the patient was witnessed to be at baseline), with\n             investigator verification that the subject has received / is receiving the correct IV\n             t-PA dose for the estimated weight prior to randomization.\n\n          6. Thrombolysis in Cerebral Infarction (TICI) 0-1 flow in the intracranial internal\n             carotid artery, M1 segment of the MCA, or carotid terminus confirmed by CT or MR\n             angiography that is accessible to the Solitaire\u2122 FR Device.\n\n          7. Subject is able to be treated within 1.5 hours (90 minutes) from CTP or DWI/PWI MR to\n             groin puncture.\n\n          8. Subject is willing to conduct protocol-required follow-up visits.\n\n          9. Subject or subject's legally authorized representative has signed and dated an\n             Informed Consent Form according to country regulations, ethics committee, and/or IRB\n             requirements.\n\n        Exclusion Criteria:\n\n          1. History of stroke in the past 3 months.\n\n          2. Female who is pregnant or lactating or has a positive pregnancy test at time of\n             admission.\n\n          3. Rapid neurological improvement prior to study randomization suggesting resolution of\n             signs/symptoms of stroke.\n\n          4. Known serious sensitivity to radiographic contrast agents.\n\n          5. Current participation in another investigational drug or device treatment study.\n\n          6. Uncontrolled hypertension defined as systolic blood pressure > 185 or diastolic blood\n             pressure > 110 that cannot be controlled except with continuous parenteral\n             antihypertensive medication.\n\n          7. Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency.\n             (Patients without history or suspicion of coagulopathy do not require INR or\n             prothrombin time lab results to be available prior to enrollment.)\n\n          8. Warfarin therapy with INR greater than 1.7.\n\n          9. Low molecular Weight Heparins (such as Dalteparin, Enoxaparin, Tinzaparin,\n             Fondaparinux) as DVT prophylaxis or in full dose within the last 24 hours from\n             screening.\n\n         10. Subject who has received heparin or a direct thrombin inhibitor (e.g. rivaroxaban,\n             Angiomax\u2122, argatroban, Refludan\u2122) within the last 48 hours must have a normal partial\n             thromboplastin time (PTT) to be eligible.\n\n         11. Subject who has received factor Xa inhibitor therapy (e.g. dabigatran) within the\n             past 24 hours must have a normal ecarin clotting time to be eligible.  Subject who\n             has received factor Xa inhibitor therapy more than 24 hours ago but less than 48\n             hours ago must have a normal partial thromboplastin time (PTT) to be eligible.\n\n         12. Baseline lab values: glucose < 50 mg/dl or > 400 mg/dl, platelets < 100,000, or Hct <\n             25.\n\n         13. Renal Failure as defined by a serum creatinine > 2.0 or Glomerular Filtration Rate\n             [GFR] < 30.\n\n         14. Subject who requires hemodialysis or peritoneal dialysis, or who have a\n             contraindication to an angiogram for whatever reason.\n\n         15. Life expectancy of less than 90 days.\n\n         16. Previous intra-cranial hemorrhage, neoplasm, subarachnoid hemorrhage, cerebral\n             aneurysm, or arteriovenous malformation.\n\n         17. Clinical presentation suggests a subarachnoid hemorrhage, even if initial CT or MRI\n             scan is normal.\n\n         18. Presumed septic embolus, or suspicion of bacterial endocarditis.\n\n         19. Presumed pericarditis including pericarditis after acute myocardial infarction.\n\n         20. Suspicion of aortic dissection.\n\n         21. Surgery or biopsy of parenchymal organ within 30 days.\n\n         22. Trauma with internal injuries or ulcerative wounds within 30 days.\n\n         23. Severe head trauma or head trauma with loss of consciousness within 90 days.\n\n         24. Any active or recent hemorrhage within 30 days.\n\n         25. Cerebral vasculitis.\n\n         26. Subject with a pre-existing neurological or psychiatric disease that would confound\n             the neurological and functional evaluations.\n\n        Imaging Exclusion Criteria:\n\n          1. Computed tomography (CT) or Magnetic Resonance Imaging (MRI) evidence of hemorrhage\n             on presentation.\n\n          2. CT showing hypodensity or MRI showing hyperintensity involving greater than 1/3 of\n             the middle cerebral artery (MCA) territory (or in other territories, >100 cc of\n             tissue) on presentation.\n\n          3. CT or MRI evidence of mass effect or intra-cranial tumor (except small meningioma).\n\n          4. Core Infarct and hypoperfusion:\n\n               -  MRI- or CT-assessed core infarct lesion greater than 50 cc;\n\n               -  Severe hypoperfusion lesion (10 sec or more Tmax lesion larger than 100 cc)\n\n               -  Ischemic penumbra < 15 cc and mismatch ratio \u22641.8.\n\n          5. Angiographic evidence of carotid dissection or complete cervical carotid occlusion.\n\n          6. Arterial tortuosity, calcification, pre-existing stent, and/or stenosis which would\n             prevent the device from reaching the target vessel and/or preclude safe recovery of\n             the device."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "833", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01657461", 
            "org_study_id": "NV-SFR004"
        }, 
        "intervention": [
            {
                "arm_group_label": "IV t-PA", 
                "intervention_name": "intravenous (IV) recombinant human tissue plasminogen activator (rtPA)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "IV t-PA with SOLITAIRE\u2122 FR Device", 
                "intervention_name": "Solitaire FR", 
                "intervention_type": "Device"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Plasminogen", 
                "Tissue Plasminogen Activator"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 6, 2013", 
        "location": {
            "contact": {
                "last_name": "Jennifer Gay", 
                "phone": "716-888-4811"
            }, 
            "facility": {
                "address": {
                    "city": "Buffalo", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "14203"
                }, 
                "name": "Kaleida Health/Buffalo General"
            }, 
            "investigator": {
                "last_name": "Adnan Siddiqui, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Solitaire\u2122 FR With the Intention For Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) Clinical Trial", 
        "overall_official": {
            "affiliation": "University of California, Los Angeles", 
            "last_name": "Jeffrey Saver, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "90-day global disability assessed via the blinded evaluation of modified Rankin score (mRS).", 
            "safety_issue": "No", 
            "time_frame": "90 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01657461"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Death due to any cause at 90 days", 
                "safety_issue": "Yes", 
                "time_frame": "90 days"
            }, 
            {
                "measure": "Functional independence as defined by modified Rankin Scale (mRS) score \u22642 at 90 days", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }, 
            {
                "measure": "Change in NIH Stroke Scale score at 27 \u00b13hrs post randomization", 
                "safety_issue": "No", 
                "time_frame": "27 hrs"
            }
        ], 
        "source": "Covidien", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Covidien", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}